Nagara Foundation halts gurdwara renovation work in Pakistan
Darpan News Desk IANS, 20 Jan, 2022 12:05 PM
New Delhi, Jan 20 (IANS) US-based Ranjit Nagara Foundation, which was overseeing the 'karsewa' (renovation/construction) of Gurdwara Chowa Sahib in Jhelum, Pakistan and other local gurdwaras, has notified that they has stopped the construction activities due to non-compliance of ETPB/PSGPC in providing them bills and expenditure details of the works carried out till date.
Satpreet Singh, Director of Ranjit Nagara Foundation, revealed that as per US rules, their foundation has to provide documentation of their expenditure to Internal Revenue Service, Department of Justice, annually which is further updated on the department's site for public or on before May 15, but the Evacuee Trust Property Board (ETPB) office has not provided the requisite documents till date. Thus, the NGO has to put its activities on hold.
Misappropriation of gurdwara funds by ETPB/PSGPC (Pakistan Sikh Gurdwara Parbandhak Committee) officials had been reported in the past as well.
The Nagara Foundation is largely funded by the Sikh diaspora with resources being further transferred to Pakistan
Parents have weighed in on reopening schools. Teachers have weighed in. Public health experts, too, along with cities, states and President Donald Trump.
A new opinion survey suggests Donald Trump's recent decision to slap a tariff on Canadian raw aluminum is garnering poor reviews on both sides of the border.
School districts nationwide puzzling over how to safely educate children during a pandemic have a more immediate challenge — getting 26 million bus-riding students there in the first place.
Some new details have emerged in Jeffrey Epstein's case that involve former US President Bill Clinton. According to testimony from an Espstein accuser the former American nation head was a guest at Jeffrey Epstein’s private Caribbean island.
The world’s biggest COVID-19 vaccine study got underway Monday with the first of 30,000 planned volunteers helping to test shots created by the U.S. government -- one of several candidates in the final stretch of the global vaccine race.
